Loading…
Prevalence of neuromyelitis optica spectrum disorder in the United States
Background: Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized. Objective: The objective of this study was to determine the 2022 US prevalence of NMOSD. Methods: We constructed a cross-sectional study us...
Saved in:
| Published in: | Multiple sclerosis 2024-03, Vol.30 (3), p.316-324 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c320t-76567bdb296ef4deb812c380bb0de6b631ca38470c75fa1883cd91fe227d946e3 |
| container_end_page | 324 |
| container_issue | 3 |
| container_start_page | 316 |
| container_title | Multiple sclerosis |
| container_volume | 30 |
| creator | Briggs, Farren BS Shaia, Jacqueline |
| description | Background:
Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized.
Objective:
The objective of this study was to determine the 2022 US prevalence of NMOSD.
Methods:
We constructed a cross-sectional study using aggregated electronic health record data for 25.7 million patients who had a 2022 clinical encounter. The data originated from the TriNetX US Collaborative Network of 55 healthcare organizations that span all 50 states. NMOSD prevalence was determined by querying for age-interval, sex, and race combinations, with direct standardization to the 2022 US Census data.
Results:
There were 1772 NMOSD patients among 25,743,039 patients for a prevalence of 6.88/100,000. Prevalence was the highest in Blacks (12.99/100,000) who represented 27.7% of NMOSD patients, then Asians (9.41/100,000and Whites (5.58/100,000). Among females, the prevalence of NMOSD was 9.48/100,000, and Black and Asian females had a 2.65- and 1.94-times higher prevalence than White females. In males, the prevalence of NMOSD was 3.52/100,000 and it did not differ by race. We observed a 3/5:1 female-to-male ratio in NMOSD. The age- and sex-adjusted 2022 estimate of persons with NMOSD in the United States was 15,413 females and 6233 males.
Conclusion:
We estimate that there were near 22,000 Americans living with NMOSD in 2022. |
| doi_str_mv | 10.1177/13524585231224683 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2929096826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_13524585231224683</sage_id><sourcerecordid>2956071112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-76567bdb296ef4deb812c380bb0de6b631ca38470c75fa1883cd91fe227d946e3</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgiq3VB3AjATdupuYyk8tSipdCQUG7HjLJGZ0yl5pkhL69U1oVFFcJ5Dt_Dj9C55RMKZXymvKMpZnKGKeMpULxAzSmqZQJ0ZIcDvfhPdmCEToJYUUIkZJnx2jEFZNaKj1G8ycPH6aG1gLuStxC77tmA3UVq4C7dayswWENNvq-wa4KnXfgcdXi-AZ42VYRHH6OJkI4RUelqQOc7c8JWt7dvsweksXj_Xx2s0gsZyQmUmRCFq5gWkCZOigUZZYrUhTEgSgEp9ZwlUpiZVYaqhS3TtMSGJNOpwL4BF3tcte-e-8hxLypgoW6Ni10fciZZppooZgY6OUvuup63w7bDSoTRFJK2aDoTlnfheChzNe-aozf5JTk257zPz0PMxf75L5owH1PfBU7gOkOBPMKP9_-n_gJgsiEew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2956071112</pqid></control><display><type>article</type><title>Prevalence of neuromyelitis optica spectrum disorder in the United States</title><source>SAGE</source><creator>Briggs, Farren BS ; Shaia, Jacqueline</creator><creatorcontrib>Briggs, Farren BS ; Shaia, Jacqueline</creatorcontrib><description>Background:
Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized.
Objective:
The objective of this study was to determine the 2022 US prevalence of NMOSD.
Methods:
We constructed a cross-sectional study using aggregated electronic health record data for 25.7 million patients who had a 2022 clinical encounter. The data originated from the TriNetX US Collaborative Network of 55 healthcare organizations that span all 50 states. NMOSD prevalence was determined by querying for age-interval, sex, and race combinations, with direct standardization to the 2022 US Census data.
Results:
There were 1772 NMOSD patients among 25,743,039 patients for a prevalence of 6.88/100,000. Prevalence was the highest in Blacks (12.99/100,000) who represented 27.7% of NMOSD patients, then Asians (9.41/100,000and Whites (5.58/100,000). Among females, the prevalence of NMOSD was 9.48/100,000, and Black and Asian females had a 2.65- and 1.94-times higher prevalence than White females. In males, the prevalence of NMOSD was 3.52/100,000 and it did not differ by race. We observed a 3/5:1 female-to-male ratio in NMOSD. The age- and sex-adjusted 2022 estimate of persons with NMOSD in the United States was 15,413 females and 6233 males.
Conclusion:
We estimate that there were near 22,000 Americans living with NMOSD in 2022.</description><identifier>ISSN: 1352-4585</identifier><identifier>ISSN: 1477-0970</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/13524585231224683</identifier><identifier>PMID: 38279789</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Autoimmune diseases ; Demyelination ; Electronic medical records ; Females ; Males ; Neuromyelitis ; Patients ; Standardization</subject><ispartof>Multiple sclerosis, 2024-03, Vol.30 (3), p.316-324</ispartof><rights>The Author(s), 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c320t-76567bdb296ef4deb812c380bb0de6b631ca38470c75fa1883cd91fe227d946e3</cites><orcidid>0000-0003-0903-1359</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924,79235</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38279789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Briggs, Farren BS</creatorcontrib><creatorcontrib>Shaia, Jacqueline</creatorcontrib><title>Prevalence of neuromyelitis optica spectrum disorder in the United States</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized.
Objective:
The objective of this study was to determine the 2022 US prevalence of NMOSD.
Methods:
We constructed a cross-sectional study using aggregated electronic health record data for 25.7 million patients who had a 2022 clinical encounter. The data originated from the TriNetX US Collaborative Network of 55 healthcare organizations that span all 50 states. NMOSD prevalence was determined by querying for age-interval, sex, and race combinations, with direct standardization to the 2022 US Census data.
Results:
There were 1772 NMOSD patients among 25,743,039 patients for a prevalence of 6.88/100,000. Prevalence was the highest in Blacks (12.99/100,000) who represented 27.7% of NMOSD patients, then Asians (9.41/100,000and Whites (5.58/100,000). Among females, the prevalence of NMOSD was 9.48/100,000, and Black and Asian females had a 2.65- and 1.94-times higher prevalence than White females. In males, the prevalence of NMOSD was 3.52/100,000 and it did not differ by race. We observed a 3/5:1 female-to-male ratio in NMOSD. The age- and sex-adjusted 2022 estimate of persons with NMOSD in the United States was 15,413 females and 6233 males.
Conclusion:
We estimate that there were near 22,000 Americans living with NMOSD in 2022.</description><subject>Autoimmune diseases</subject><subject>Demyelination</subject><subject>Electronic medical records</subject><subject>Females</subject><subject>Males</subject><subject>Neuromyelitis</subject><subject>Patients</subject><subject>Standardization</subject><issn>1352-4585</issn><issn>1477-0970</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10MtKAzEUBuAgiq3VB3AjATdupuYyk8tSipdCQUG7HjLJGZ0yl5pkhL69U1oVFFcJ5Dt_Dj9C55RMKZXymvKMpZnKGKeMpULxAzSmqZQJ0ZIcDvfhPdmCEToJYUUIkZJnx2jEFZNaKj1G8ycPH6aG1gLuStxC77tmA3UVq4C7dayswWENNvq-wa4KnXfgcdXi-AZ42VYRHH6OJkI4RUelqQOc7c8JWt7dvsweksXj_Xx2s0gsZyQmUmRCFq5gWkCZOigUZZYrUhTEgSgEp9ZwlUpiZVYaqhS3TtMSGJNOpwL4BF3tcte-e-8hxLypgoW6Ni10fciZZppooZgY6OUvuup63w7bDSoTRFJK2aDoTlnfheChzNe-aozf5JTk257zPz0PMxf75L5owH1PfBU7gOkOBPMKP9_-n_gJgsiEew</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Briggs, Farren BS</creator><creator>Shaia, Jacqueline</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0903-1359</orcidid></search><sort><creationdate>20240301</creationdate><title>Prevalence of neuromyelitis optica spectrum disorder in the United States</title><author>Briggs, Farren BS ; Shaia, Jacqueline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-76567bdb296ef4deb812c380bb0de6b631ca38470c75fa1883cd91fe227d946e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Autoimmune diseases</topic><topic>Demyelination</topic><topic>Electronic medical records</topic><topic>Females</topic><topic>Males</topic><topic>Neuromyelitis</topic><topic>Patients</topic><topic>Standardization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Briggs, Farren BS</creatorcontrib><creatorcontrib>Shaia, Jacqueline</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Briggs, Farren BS</au><au>Shaia, Jacqueline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of neuromyelitis optica spectrum disorder in the United States</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>30</volume><issue>3</issue><spage>316</spage><epage>324</epage><pages>316-324</pages><issn>1352-4585</issn><issn>1477-0970</issn><eissn>1477-0970</eissn><abstract>Background:
Neuromyelitis optic spectrum disorder (NMOSD) is a rare demyelinating, autoimmune disease and the burden in United States is not well characterized.
Objective:
The objective of this study was to determine the 2022 US prevalence of NMOSD.
Methods:
We constructed a cross-sectional study using aggregated electronic health record data for 25.7 million patients who had a 2022 clinical encounter. The data originated from the TriNetX US Collaborative Network of 55 healthcare organizations that span all 50 states. NMOSD prevalence was determined by querying for age-interval, sex, and race combinations, with direct standardization to the 2022 US Census data.
Results:
There were 1772 NMOSD patients among 25,743,039 patients for a prevalence of 6.88/100,000. Prevalence was the highest in Blacks (12.99/100,000) who represented 27.7% of NMOSD patients, then Asians (9.41/100,000and Whites (5.58/100,000). Among females, the prevalence of NMOSD was 9.48/100,000, and Black and Asian females had a 2.65- and 1.94-times higher prevalence than White females. In males, the prevalence of NMOSD was 3.52/100,000 and it did not differ by race. We observed a 3/5:1 female-to-male ratio in NMOSD. The age- and sex-adjusted 2022 estimate of persons with NMOSD in the United States was 15,413 females and 6233 males.
Conclusion:
We estimate that there were near 22,000 Americans living with NMOSD in 2022.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>38279789</pmid><doi>10.1177/13524585231224683</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0903-1359</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2024-03, Vol.30 (3), p.316-324 |
| issn | 1352-4585 1477-0970 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2929096826 |
| source | SAGE |
| subjects | Autoimmune diseases Demyelination Electronic medical records Females Males Neuromyelitis Patients Standardization |
| title | Prevalence of neuromyelitis optica spectrum disorder in the United States |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A31%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20neuromyelitis%20optica%20spectrum%20disorder%20in%20the%20United%20States&rft.jtitle=Multiple%20sclerosis&rft.au=Briggs,%20Farren%20BS&rft.date=2024-03-01&rft.volume=30&rft.issue=3&rft.spage=316&rft.epage=324&rft.pages=316-324&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/13524585231224683&rft_dat=%3Cproquest_cross%3E2956071112%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c320t-76567bdb296ef4deb812c380bb0de6b631ca38470c75fa1883cd91fe227d946e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2956071112&rft_id=info:pmid/38279789&rft_sage_id=10.1177_13524585231224683&rfr_iscdi=true |